Quest Partners LLC Acquires 11,335 Shares of Prestige Consumer Healthcare Inc. (NYSE:PBH)

Quest Partners LLC lifted its holdings in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) by 2,582.0% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 11,774 shares of the company’s stock after buying an additional 11,335 shares during the period. Quest Partners LLC’s holdings in Prestige Consumer Healthcare were worth $849,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of PBH. Boston Trust Walden Corp bought a new position in Prestige Consumer Healthcare in the 3rd quarter worth $41,785,000. Ariel Investments LLC grew its position in shares of Prestige Consumer Healthcare by 10.7% in the second quarter. Ariel Investments LLC now owns 2,835,203 shares of the company’s stock valued at $195,204,000 after purchasing an additional 274,212 shares during the last quarter. Allspring Global Investments Holdings LLC increased its stake in shares of Prestige Consumer Healthcare by 26.0% in the second quarter. Allspring Global Investments Holdings LLC now owns 1,320,125 shares of the company’s stock worth $90,891,000 after purchasing an additional 272,773 shares during the period. Victory Capital Management Inc. lifted its position in shares of Prestige Consumer Healthcare by 9.0% during the 2nd quarter. Victory Capital Management Inc. now owns 2,074,460 shares of the company’s stock worth $142,827,000 after purchasing an additional 171,357 shares during the last quarter. Finally, F M Investments LLC bought a new stake in Prestige Consumer Healthcare during the 2nd quarter valued at approximately $11,162,000. Institutional investors own 99.95% of the company’s stock.

Insider Buying and Selling at Prestige Consumer Healthcare

In related news, SVP Mary Beth Fritz sold 9,885 shares of the stock in a transaction dated Tuesday, November 12th. The shares were sold at an average price of $81.97, for a total transaction of $810,273.45. Following the completion of the sale, the senior vice president now owns 18,835 shares in the company, valued at $1,543,904.95. This trade represents a 34.42 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Adel Mekhail sold 9,063 shares of the business’s stock in a transaction dated Tuesday, November 12th. The shares were sold at an average price of $82.00, for a total transaction of $743,166.00. Following the completion of the transaction, the executive vice president now owns 18,365 shares in the company, valued at approximately $1,505,930. This trade represents a 33.04 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 38,810 shares of company stock valued at $3,187,300 in the last 90 days. 1.60% of the stock is currently owned by company insiders.

Prestige Consumer Healthcare Trading Up 1.7 %

Shares of PBH opened at $84.09 on Friday. The stock’s 50-day moving average price is $73.91 and its 200 day moving average price is $70.48. The company has a quick ratio of 2.10, a current ratio of 3.56 and a debt-to-equity ratio of 0.61. The firm has a market capitalization of $4.15 billion, a price-to-earnings ratio of 20.47, a P/E/G ratio of 2.32 and a beta of 0.47. Prestige Consumer Healthcare Inc. has a 12-month low of $56.61 and a 12-month high of $84.28.

Prestige Consumer Healthcare (NYSE:PBH) last released its quarterly earnings data on Thursday, November 7th. The company reported $1.09 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $1.09. The business had revenue of $283.79 million for the quarter, compared to analysts’ expectations of $282.09 million. Prestige Consumer Healthcare had a return on equity of 12.23% and a net margin of 18.54%. Prestige Consumer Healthcare’s quarterly revenue was down .9% on a year-over-year basis. During the same period in the previous year, the business posted $1.07 earnings per share. As a group, research analysts predict that Prestige Consumer Healthcare Inc. will post 4.45 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have commented on PBH. Jefferies Financial Group reaffirmed a “hold” rating and issued a $76.00 price target (up from $70.00) on shares of Prestige Consumer Healthcare in a research report on Tuesday, September 24th. DA Davidson restated a “buy” rating and issued a $95.00 price objective on shares of Prestige Consumer Healthcare in a research note on Monday, November 11th. One investment analyst has rated the stock with a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $83.67.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.